ChitogenX CEO Phil Deschamps joins Natalie Stoberman from the Proactive newsroom to share its latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine.
Deschamps says the company has obtained a $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (“NSERC”) and Prima Québec. He adds the company will be collaborating with Polytechnique Montréal throughout the four year grant to advance the scientific development, expand the scope of indications, develop new biomaterials for regenerative medicine and accelerate the commercial readiness of the Company’s flagship ORTHO-R technology platform.